Walgreens Boots Alliance, Inc.’s Stock Price Suffers 3.57% Drop, Trading at $8.65

Walgreens Boots Alliance, Inc. (WBA)

8.65 USD -0.32 (-3.57%) Volume: 24.48M

Walgreens Boots Alliance, Inc.’s stock price is currently at 8.65 USD, experiencing a decrease of -3.57% in today’s trading session with a trading volume of 24.48M, reflecting a significant YTD drop of -66.87%, highlighting its fluctuating performance on the stock market.

Latest developments on Walgreens Boots Alliance, Inc.

Walgreens Boots Alliance stock price saw a significant drop after Bank of America lowered its price target to $7.50 from $11. This news came amidst a flurry of events surrounding the company, including participation in TD Cowen’s 9th Annual FutureHealth Conference and the filing of a class action lawsuit seeking recovery for investors. With shares trading slightly higher, investors are closely watching the developments, especially after Walgreens was hit with a lawsuit over generic cold medicine. As stakeholders assess the situation, equities analysts have issued forecasts for the company’s Q4 2024 earnings, providing some insight into the future trajectory of Walgreens Boots Alliance stock.

Walgreens Boots Alliance, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have provided bullish coverage on Walgreens Boots Alliance, highlighting the company’s focus on enhancing digital and operational efficiency to expand margins. In a recent research report titled “Walgreens Boots Alliance: Enhancing Digital & Operational Efficiency To Expand Margins! – Major Drivers,” the analysts discuss the company’s performance for the third quarter of Fiscal Year 2024. While the results presented reflect mixed outcomes in various areas of the business, the report aims to provide a comprehensive view of both positive developments and drawbacks evident in the quarter under review.

Furthermore, Baptista Research continues its bullish sentiment on Walgreens Boots Alliance in another research report titled “Walgreens Boots Alliance Inc.: Redefining Relationships & Creating Value with Payers! – Major Drivers.” The analysts note that the company’s latest earnings for the second quarter aligned with expectations despite challenges in the U.S. retail environment. With an adjusted EPS of $1.20, the company demonstrated cost discipline and good execution in the U.S. Retail Pharmacy segment, along with solid international performance. Baptista Research evaluates different factors that could influence the company’s stock price in the near future and conducts an independent valuation using a Discounted Cash Flow (DCF) methodology.

A look at Walgreens Boots Alliance, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Walgreens Boots Alliance has received high scores in both the Value and Dividend categories, indicating a positive outlook for the company’s financial health and ability to provide returns to investors. However, the lower scores in Growth, Resilience, and Momentum suggest that there may be challenges ahead in terms of expanding its business, weathering economic downturns, and maintaining market momentum.

Despite facing some obstacles in the areas of Growth, Resilience, and Momentum, Walgreens Boots Alliance remains a strong player in the retail drugstore industry. With a wide range of products and services, including prescription and non-prescription drugs, health services, and general goods, the company continues to cater to the diverse needs of its customers. Investors may find comfort in the high Value and Dividend scores, indicating stability and potential for long-term growth.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma